Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueTax ProvisionsTax Rate
Others
Ratios

Metlife (MET) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Metlife (MET) over the last 17 years, with Q3 2025 value amounting to $818.0 million.

  • Metlife's Net Income towards Common Stockholders fell 3584.31% to $818.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 205.0%. This contributed to the annual value of $4.2 billion for FY2024, which is 20623.19% up from last year.
  • As of Q3 2025, Metlife's Net Income towards Common Stockholders stood at $818.0 million, which was down 3584.31% from $698.0 million recorded in Q2 2025.
  • Metlife's 5-year Net Income towards Common Stockholders high stood at $3.4 billion for Q2 2021, and its period low was $14.0 million during Q1 2023.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $881.0 million (2022), whereas its average is $1.0 billion.
  • In the last 5 years, Metlife's Net Income towards Common Stockholders tumbled by 9910.88% in 2023 and then skyrocketed by 561428.57% in 2024.
  • Metlife's Net Income towards Common Stockholders (Quarter) stood at $1.5 billion in 2021, then increased by 4.87% to $1.5 billion in 2022, then tumbled by 62.94% to $574.0 million in 2023, then skyrocketed by 115.85% to $1.2 billion in 2024, then crashed by 33.98% to $818.0 million in 2025.
  • Its last three reported values are $818.0 million in Q3 2025, $698.0 million for Q2 2025, and $879.0 million during Q1 2025.